Affiliation:
1. Department of Medical Microbiology and Immunology, Center for Research in Anti-Infectives and Biotechnology, Creighton University School of Medicine, Omaha, Nebraska
Abstract
ABSTRACT
Little is known about mechanisms involved in high-level expression of plasmid-associated
ampC
genes. The sequence for
bla
MIR-1
has been elucidated, and the gene is not inducible. Although the sequence for the promoter (prA) that drives expression of
Enterobacter cloacae
chromosomal
ampC
is present upstream of
bla
MIR-1
, high-level expression from
bla
MIR-1
is directed from a hybrid promoter (prB) located further upstream of prA. The purpose of this study was to determine the influence of each promoter on
bla
MIR-1
expression and β-lactam resistance. RNA expression by deletion clones with both promoters was measured and compared to that by clones in which −35 and/or −10 elements of prA and/or prB were altered. Primer extension revealed two start sites for
bla
MIR-1
transcription. Expression of
bla
MIR-1
in clones with both promoters was 171-fold higher than that in clones carrying only prA. In addition,
bla
MIR-1
expression from prA increased 11-fold in the presence of the prB −10 element compared to expression driven from prA alone. Ceftazidime and cefotaxime MICs increased 42- and 64-fold, respectively, for the clone expressing
bla
MIR-1
from both promoters compared to expression from prA alone. The upstream promoter prB of
bla
MIR-1
is solely responsible for high-level expression required for cefotaxime and ceftazidime resistance. These data suggest that resistance to extended-spectrum cephalosporins mediated by noninducible plasmid-associated
ampC
genes requires the formation of novel promoter elements that are capable of increasing
ampC
expression.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献